- •Sjögren’s Syndrome
- •Foreword
- •Contents
- •Contributors
- •1.1 Primary Sjögren’s Syndrome
- •1.1.1 Diagnostic Criteria
- •1.1.2 Incidence
- •1.1.3 Prevalence
- •References
- •2.1 Introduction
- •2.2 Genetic Epidemiology of SS
- •2.3 Key Concepts in Genetics, Transcriptomics, and Proteomics
- •2.4 Candidate Genes and SS Pathogenesis
- •2.5 Gene Expression Studies in SS
- •2.6 Protein Expression Studies in SS
- •2.7 Future Directions
- •References
- •3.1 Introduction
- •3.2 Characteristics of Autoimmune Lesions
- •3.3 Epithelial Cells as Key Regulators of Autoimmune Responses
- •3.4 Tissue Injury and Repair
- •3.4.1 Functional Impairment of Glands and Autonomic Nervous System Involvement
- •3.4.2 Extracellular Matrix and Tissue Damage
- •3.5 Pathogenetic Factors
- •3.5.1 Genetic Predisposition
- •3.5.2 Environmental Factors
- •3.5.3 Hormonal
- •3.6 Conclusions/Summary
- •References
- •4.1 Hepatitis C Virus
- •4.2 Hepatitis B Virus
- •4.5 Coxsackieviruses
- •4.6 Herpes Viruses
- •4.7 Human Parvovirus B19
- •4.8 Conclusion
- •References
- •5.1 The Role of T Cells in SjS
- •5.2 The Role of B Cells in SjS
- •5.2.1 The Impact of B Cell Cytokines
- •5.2.2 Ontogeny of B Lymphocytes
- •5.2.3 Subpopulations of B Cells
- •5.2.4 B Cell Monoclonal Expansion
- •5.3 B Cells Are Not Dispensable
- •5.3.1 B Cell Chemokines and Antibody Production
- •5.3.2 Peculiarities of B Cell Products: Cytokines and IgA Autoantibodies
- •5.3.3 Intrinsic Abnormalities of B Cells in Primary SjS
- •5.4 Conclusion
- •References
- •6.1 Introduction
- •6.3 Objective Determination of Salivary Flow
- •6.4 Etiology of Xerostomia
- •6.5 Orofacial Manifestations in SS
- •6.5.1 Salivary Involvement
- •6.5.2 Neurological Involvement
- •6.6 Sialochemical Changes in SS
- •6.7 Hyposalivation: Clinical Features and Complications
- •6.7.1 Clinical Features
- •6.7.2 Examination
- •6.7.3 Clinical Signs of Hyposalivation
- •6.7.4 Effect of Hyposalivation on Quality of Life
- •6.7.5 Management of Hyposalivation
- •6.7.6 Chronic Complications of Hyposalivation
- •Box 6.1: Chronic Complications of Hyposalivation
- •6.7.6.1 Dental Caries
- •Box 6.2: Strategies for Reducing Dental Caries in Patients with Sjögren’s Syndrome
- •6.7.6.2 Periodontal Health
- •6.7.6.3 Oral Functional Impairments
- •6.7.6.4 Oral Infections
- •Box 6.3: Factors Predisposing to Oral Candidiasis
- •6.7.6.6 Angular Stomatitis
- •6.7.6.7 Candidiasis
- •6.7.6.8 Bacterial Sialadenitis
- •6.7.6.9 Oral Ulceration
- •6.8 Salivary Gland Enlargement
- •6.8.1 Box 6.5: Non-Salivary Causes of Salivary Gland Enlargement
- •6.9 Salivary Swelling in SS
- •References
- •Key Websites (Accessed Dec 19, 2009)
- •7.1 Sjögren’s Syndrome: A Disease of the Lacrimal Functional Unit
- •7.2 Components of the Lacrimal Functional Unit
- •7.3 Lacrimal Gland
- •7.4 Conjunctiva
- •7.5 Cornea
- •7.6 Meibomian Glands and Eyelids
- •7.7 Neural Innervation
- •7.8 Mechanisms of Dysfunction
- •7.8.1 Lacrimal Gland
- •7.8.2 Ocular Surface
- •7.9 Diagnosis of Ocular Involvement in Sjögren’s Syndrome
- •7.10 Treatment of LFU Dysfunction
- •References
- •8.1 Introduction
- •8.2 Otologic Manifestations
- •8.3 Sinus and Nasal Manifestations
- •8.4 Laryngopharyngeal and Tracheal Manifestations
- •References
- •9.1 Epidemiology of Fatigue
- •9.2 Assessing Fatigue
- •9.4 Relationship of Fatigue to Cognitive Symptoms and to Depression
- •9.5 Fatigue Viewed From the Physiological Perspective: Relationships Between Fatigue, Sleep Quality, and Neuroendocrine Function
- •9.6 Relationship Between Fibromyalgia and SS
- •9.7 Management of Pain and Fatigue
- •9.8 Summary
- •References
- •10.1 Introduction
- •10.2 Arthralgias and Arthritis
- •10.3 Arthritis: Patterns of Expression
- •10.4 Differential Diagnosis: RA, SLE, and Other Arthropathies
- •References
- •11.1 Introduction
- •11.2 Epidemiology
- •11.3 Skin Changes Encountered in Primary SjS
- •11.3.1 Pruritus
- •11.3.2 Annular Erythema of SjS
- •11.3.3 Eyelid Dermatitis
- •11.3.4 Panniculitis
- •11.3.5 Primary Nodular Cutaneous Amyloidosis
- •11.3.6 B Cell Lymphoma
- •11.4 Skin Changes Encountered in Secondary SjS
- •11.4.1 Skin Changes Associated with Lupus Erythematosus
- •References
- •12.1 Introduction
- •12.2 Epidemiology
- •12.3 Histopathology
- •12.4 Laboratory Findings
- •12.5 Pathogenesis
- •12.6 Clinical Findings
- •12.7 Skin
- •12.8 Peripheral and Central Nervous System
- •12.9 Other Organs
- •12.10 Vasculitis and Mortality
- •12.11 Treatment
- •References
- •13.1 Introduction
- •13.2 Pericarditis
- •13.3 Myocarditis
- •13.4 Valvular Abnormalities
- •13.5 Diastolic Dysfunction
- •13.6 Atrioventricular Block
- •13.7 Subclinical Atherosclerosis
- •13.8 Pulmonary Arterial Hypertension
- •13.9 Autonomic Cardiovascular Dysfunction
- •13.10 Therapeutic Management
- •13.11 Conclusion
- •References
- •14.1 Introduction
- •14.2 Airway Disease
- •14.2.1 Overview
- •14.2.2 Pathology
- •14.2.3 Imaging Studies
- •14.3 Interstitial Lung Disease
- •14.3.1 Overview
- •14.3.2 Pathology
- •14.3.4 Usual Interstitial Pneumonia
- •14.3.5 Follicular Bronchiolitis
- •14.3.6 Lymphocytic Interstitial Pneumonia
- •14.3.7 Cryptogenic Organizing Pneumonia
- •14.3.8 Clinical Features
- •14.3.9 Imaging Studies
- •14.4 Pleuritis
- •14.5 Diagnosis and Management
- •References
- •15.1 Evaluation of the Sjögren’s Syndrome and Raynaud’s Phenomenon
- •15.2 Management of Raynaud’s Phenomenon
- •15.2.1 Vasodilator Therapy
- •15.2.2 Calcium Channel Blockers
- •15.2.3 Adrenergic Blockers
- •15.2.4 Nitrates
- •15.2.5 Phosphodiesterase Inhibitors
- •15.2.6 Prostacyclins
- •15.2.7 Other Agents
- •15.3 Surgical Options
- •15.3.1 Sympathectomies
- •15.3.2 Management of Critical Digital Ischemia
- •References
- •16.1 Dysphagia
- •16.3 Chronic Gastritis
- •16.5 Association with Celiac Disease
- •16.6 Intestinal Vasculitis
- •16.7 Other Intestinal Diseases
- •16.8 Conclusion
- •References
- •17.1 Introduction
- •17.2 Primary Biliary Cirrhosis (PBC)
- •17.2.2 Similarities, Differences, and Overlap Among SS and PBC
- •17.2.3 Epithelium Involvement
- •17.2.4 Animal Models
- •17.2.5 Histology and Serology
- •17.3 Autoimmune Hepatitis (AIH)
- •17.4 Hepatitis C Virus (HCV) Infection and Sicca Syndrome
- •17.5 Algorithm for the Diagnosis of Liver Involvement in SS
- •References
- •18.1 Introduction
- •18.3 Involvement of the Pancreas in SjS
- •18.3.1 Clinical Presentation
- •18.3.2 Autoantibodies
- •18.3.3 Pancreatic Enzymes
- •18.3.4 Pathology
- •18.3.5 Imaging Studies of the Pancreas
- •18.4 Autoimmune Pancreatitis
- •18.4.1 Introduction
- •18.4.2 Clinical Features
- •18.4.3 Imaging
- •18.4.4 Serology
- •18.4.5 Pathology
- •18.4.6 Diagnostic Criteria
- •18.5.1 Introduction
- •18.5.2 Nomenclature
- •18.5.3 Clinical Manifestations
- •18.5.4 Serological Issues
- •18.5.5 Pathology
- •18.5.6 Diagnostic Criteria
- •18.6 Conclusions
- •References
- •19.1 Introduction
- •19.2 Interstitial Nephritis in Primary Sjögren’s Syndrome
- •19.2.1 Historical Aspects
- •19.2.2 Clinical Features
- •19.2.3 Histology
- •19.2.4 Pathogenesis
- •19.2.5 Differential Diagnosis
- •19.2.6 Treatment
- •19.3 Glomerulonephritis in Primary Sjögren’s Syndrome
- •19.3.1 Historical Aspects
- •19.3.2 Clinical Features
- •19.3.3 Histology
- •19.3.4 Pathogenesis
- •19.3.5 Differential Diagnosis
- •19.3.6 Treatment
- •19.4 Painful Bladder Syndrome/Interstitial Cystitis and Primary Sjögren’s Syndrome
- •19.4.1 Historical Aspects
- •19.4.2 Clinical, Cytoscopic, and Histologic Features
- •19.4.3 Pathogenesis and Association with Sjögren’s Syndrome
- •19.4.4 Differential Diagnosis
- •19.4.5 Treatment
- •References
- •20.2 Cerebral Lesions
- •20.3 Differential Diagnosis with Multiple Sclerosis, Neuromyelitis Optica, and Antiphospholipid Syndrome
- •20.4 Cranial Nerve Involvement
- •20.5 Diagnostic Algorithm of SS Patient with CNS Lesions, Myelitis, Meningitis
- •References
- •21.3 Sensorimotor Demyelinating Polyneuropathy (CIDP)
- •21.4 Multiple Mononeuropathy or Mononeuritis Multiplex
- •21.5 Sensory Ataxic Neuronopathy
- •21.6 Small Fiber Painful Sensory Neuropathy
- •21.7 Restless Leg Syndrome
- •References
- •22.1 Introduction
- •22.2 Pathogenesis of Autonomic Dysfunction in pSS
- •22.3 Diagnostic Tests
- •22.4 Parasympathetic and Sympathetic Disorders
- •22.4.1 Secretomotor Disorder
- •22.4.2 Urinary Disorder
- •22.4.3 Gastrointestinal Disorder
- •22.4.4 Pupillomotor Disorder
- •22.4.5 Orthostatic Intolerance
- •22.4.6 Vasomotor Disorder
- •22.5 Diagnostic Algorithm of pSS Patient with Autonomic Dysfunction
- •22.6 Treatment
- •References
- •23.1 Introduction
- •23.5 Prolactin and Sjögren Syndrome
- •23.7 Perspectives of Hormonal Treatment on Sjögren Syndrome
- •23.8 Conclusions
- •References
- •24.1 Introduction
- •24.2 Gynecological Manifestations in Sjögren’s Syndrome
- •24.3.1 Epidemiology and Clinical Features of NLS and Congenital Heart Block (CHB)
- •24.3.2 Maternal and Fetal Outcomes in NLS
- •24.3.3 Diagnosis
- •24.3.4 Risk Factors
- •24.3.5 Pathogenesis of Congenital Heart Block
- •References
- •25.1 Introduction
- •25.2 Serum Proteins
- •25.2.1 Acute Phase Reactants
- •25.2.2 Gammaglobulins
- •25.2.2.1 Polyclonal Hypergammaglobulinemia
- •25.2.2.3 Circulating Monoclonal Immunoglobulins
- •25.3 Hematological Abnormalities
- •25.3.1 Normocytic Anemia
- •25.3.2 Autoimmune Hemolytic Anemia
- •25.3.3 Aplastic Anemia
- •25.3.4 Pure Red Cell Aplasia
- •25.3.5 Myelodysplasia
- •25.3.6 Pernicious Anemia
- •25.3.7 Leukopenia
- •25.3.8 Lymphopenia
- •25.3.9 Neutropenia
- •25.3.10 Eosinophilia
- •25.3.11 Thrombocytopenia
- •25.4 Conclusions
- •References
- •26.2 Questionnaires
- •26.3 Ocular Tests
- •26.3.1 Schirmer Test
- •26.3.2 Vital Dyes
- •26.3.3 Rose Bengal
- •26.3.4 Fluorescein
- •26.3.5 Lissamine Green
- •26.3.7 Tear Osmolarity
- •26.3.8 Tear Meniscus
- •26.3.9 Tear Proteins
- •26.3.10 Ferning Test
- •26.3.11 Ocular Cytology
- •26.4 Oral Tests
- •26.4.1 Wafer Test
- •26.4.2 Whole Saliva Flow Collection
- •26.4.3 Saxon Test
- •26.4.5 Impression Cytology
- •26.5 Conclusion
- •References
- •27.1 Salivary Scintigraphy
- •27.2 Sialography
- •27.3 Ultrasound
- •27.4 Tomography
- •27.5 Magnetic Resonance
- •27.6 Salivary Gland Biopsy
- •27.6.1 Labial Gland Biopsy
- •27.6.2 Daniels’ Technique
- •27.6.3 Punch Biopsy
- •27.6.4 Major Salivary Gland Biopsy
- •27.6.5 Lacrimal Gland Biopsy
- •27.6.6 Focus Score
- •27.7 Is There an Alternative to Labial Salivary Gland Biopsy?
- •References
- •28.1 Antinuclear Antibodies
- •28.3 Antibodies Against Nonnuclear Antigens
- •28.7 Antiphospholipid Antibodies
- •28.9 Anticentromere Antibodies
- •28.12 Rheumatoid Factor and Cryoglobulins
- •28.13 Complement
- •28.14 Conclusion
- •References
- •29.1 Introduction
- •29.2 Historical Overview and Sets of Criteria
- •29.3 Preliminary European Criteria
- •References
- •30.1 Introduction
- •30.2 Clinical and Serological Peculiarities of Sjögren’s Syndrome
- •30.3 Assessment of Disease Activity or Damage in Systemic Autoimmune Diseases
- •30.4 Methodological Procedures to Develop Disease Status Criteria
- •30.5 Development of Disease Status Indices for Sjögren’s Syndrome
- •30.5.1 The Italian Approach
- •30.5.2 The British Approach
- •30.5.3 The EULAR Initiative
- •References
- •31.1 Introduction
- •31.3 Other Generic QoL/HRQoL Measures
- •31.6 Predictors of QoL and HRQoL (WHOQoL) in PSS
- •31.7 Therapeutic Interventions
- •31.8 Conclusions and Summary
- •References
- •32.1 Introduction
- •32.2 SS Associated with Systemic Lupus Erythematosus (SLE)
- •32.3 SS Associated with Rheumatoid Arthritis (RA)
- •32.5 SS Associated with Other Systemic Autoimmune Diseases
- •32.5.1 Mixed Connective Tissue Disease
- •32.5.2 Systemic Vasculitis
- •32.5.3 Antiphospholipid Syndrome (APS)
- •32.5.4 Sarcoidosis
- •32.6.1 SS Associated with Autoimmune Thyroiditis
- •32.6.2 SS Associated with Autoimmune Liver Disease
- •32.6.3 Association of SS with Coeliac Disease
- •32.7 Conclusions
- •References
- •33.1 Introduction
- •33.2 Methodological Considerations
- •33.3 Primary Sjögren’s Syndrome and Lymphoma
- •33.3.1 Risk Levels
- •33.3.2 Lymphoma Subtypes
- •33.4 Prediction of Lymphoma
- •33.4.1 Can We Tell Who Will Develop Lymphoma and When This May Occur?
- •33.4.2 Established Risk Factors
- •33.4.3 Recently Proposed Newer Risk Factors
- •33.5 Pathogenetic Mechanisms
- •33.6 Medication and Risk of Lymphoma in SS
- •33.7 Associated Sjögren’s Syndrome and Lymphoma
- •33.8 Other Cancers in SS
- •33.9 Conclusion
- •References
- •34.1 Introduction
- •34.2 Mortality and Causes of Death in pSS
- •34.4 Conclusions
- •References
- •35.1 Introduction
- •35.2 General Considerations
- •35.3.1 Keratoconjunctivitis Sicca
- •35.3.2 Xerostomia
- •35.3.3 Systemic Dryness
- •35.3.4 Extraglandular Manifestations
- •35.4 Diagnosis
- •35.4.2 Diagnostic Methods
- •35.4.2.1 Keratoconjunctivitis Sicca
- •35.4.2.2 Xerostomia
- •35.4.2.3 Salivary Gland Biopsy
- •35.4.2.4 Immunological Tests
- •35.4.2.5 Other Laboratory Findings
- •35.5 Comorbidities and Occupational Disability
- •35.6 Treatment
- •35.6.1 Keratoconjunctivitis Sicca
- •35.6.2 Xerostomia
- •35.6.3 Management of Extraglandular Features
- •35.7 When to Refer to a Specialist
- •References
- •36.1 Background
- •36.2 General Approach to Dry Mouth
- •36.3 Additional Dental Needs of the SjS Patient
- •36.3.1 Background
- •36.4 Particular Oral Needs of the SjS Patient to Be Assessed by the Rheumatologist
- •36.5 Use of Secretagogues
- •36.5.1 Other Cholinergic Agonists
- •36.5.2 Additional Topical Treatments
- •36.5.3 Systemic Therapy
- •36.6 Oral Candidiasis
- •36.7 Treatment and Management of Cutaneous Manifestations
- •36.7.1 Treatment of Dry Skin in SjS Is Similar to Managing Xerosis in Other Conditions
- •36.7.2 Vaginal Dryness
- •36.7.3 Special Precautions at the Time of Surgery
- •References
- •37.1 Introduction
- •37.2 Marginal Zone (MZ) Lymphomas
- •37.2.1 Extranodal Marginal Zone Lymphomas of MALT Type
- •37.2.2 Therapeutic Approaches of MALT Lymphomas
- •37.2.4 Managing NMZL
- •37.3.1 Histology and General Considerations
- •37.3.2 Treatment of DLBCL
- •37.4 Conclusions
- •References
- •38.1 Introduction
- •38.2 Antimalarials
- •38.4 Glucocorticoids
- •38.5 Azathioprine
- •38.6 Cyclophosphamide
- •38.7 Methotrexate
- •38.8 Cyclosporine
- •38.9 Conclusion
- •References
- •39.3 Mycophenolic Acid
- •39.4 Mizoribine
- •39.5 Rebamipide
- •39.6 Diquafosol
- •39.7 Cladribine
- •39.8 Fingolimod
- •References
- •40.1.2.1 Serum BAFF in SS
- •40.1.3 BAFF Is Secreted by Resident Cells of Target Organs of Autoimmunity
- •40.2 Rituximab in SS
- •40.2.1 The Different Studies Assessing Rituximab in SS
- •40.2.2 Safety of Rituximab
- •40.2.3 Increase of BAFF After Rituximab Therapy
- •40.3.1 Epratuzumab
- •40.4 Conclusion
- •References
- •41.1 Introduction
- •41.2 Cytokine Targeted Therapies
- •41.2.2 Etanercept
- •41.2.3 Interferon Alpha
- •41.2.4 Emerging Anticytokine Therapies
- •41.3 T Cell Targeted Therapies
- •41.3.1 Efalizumab
- •41.3.2 Alefacept
- •41.3.3 Abatacept
- •41.4 Conclusion
- •References
- •42.1 Introduction
- •42.2 Progression and Disease Activity in SjS
- •42.2.1 Saliva
- •42.2.2 Serum
- •42.2.3 Labial or Parotid Tissue
- •42.3 Molecular Targets for Potential Therapeutic Interventions
- •42.3.1 Interferons
- •42.3.2 Cytokines
- •42.3.3 B Cell Activating Factors
- •42.3.4 B and T Cell Receptors
- •42.3.4.1 Rituximab
- •42.3.4.2 Epratuzumab
- •42.3.4.3 Abatacept
- •42.4 Gene Therapy
- •42.5 Stem Cell Therapy
- •42.6 Conclusion
- •References
- •Index
36 Therapy of Oral and Cutaneous Dryness Manifestations in Sjögren’s Syndrome |
521 |
moisture, it does not provide the lubricating properties that are characteristic of the mucin/water mixtures that constitute normal saliva.
Patients should be aware that excessive water sipping might actually reduce the mucus film in the mouth and increase symptoms. If water consumption is excessive, especially in the evening, nocturia can occur, resulting in sleep disturbance that may worsen fatigue, cognitive difficulties, and pain that some patients experience.
We advise patients to avoid acidic beverages, which may adversely affect dental enamel. Examples of common beverages and their relative acidity include:
•Carbonated waters have high acidity
•“Energy drinks” are usually acidic
•Flavored waters are often acidic
•Cola drinks pH 2.6 (Black Cherry soda: highest acidity and sugar)
•Tea, herbal pH 3.2
•Coffee pH 5.0
•Tea, black pH 5.7–7.0
•Water from tap pH 7.0 (neutral)
The maintenance of pH in the oral cavity is highly important [27]. When the pH in the oral cavity is stable, there is a decrease in the amount of demineralization that takes place. Further, the pH of the oral cavity affects the microflora [28], the biofilm, and the ability of bacteria to adhere to the dental enamel [29]. The pH and buffer capacity in the parotid saliva of individuals with SjS are much lower when compared with those in normal control individuals. The buffer systems responsible for the human saliva-buffering capacity include bicarbonate, phosphate, and protein. Even a minor drop in pH can result in dental caries or damage to the teeth by erosion [30, 31].
36.3Additional Dental Needs of the SjS Patient
36.3.1Background
At most medical centers and for rheumatologists in practice, communication with dentists and specialists in Oral Medicine is quite limited. However, rheumatologists need to be familiar with the terminology used by Oral Medicine in order to read the relevant literature published on SjS, and to advise patients regarding particular dental procedures that may influence their medical status. Radiation therapists have developed a close working relationship with Oral Medicine to prevent and treat oral complications, but similar interactions for rheumatologists are uncommon. Therefore, we will review basic terminology and approaches as a background to specific discussions listed below.
522 |
R.I. Fox and C.M. Fox |
Table 36.1 Saliva content and stimulation in normal individuals
Saliva functions
•Saliva also breaks down food caught in the teeth, protecting them from bacteria that cause decay. Furthermore, saliva lubricates and protects the teeth, the tongue, and the tender tissues inside the mouth.
•Saliva also plays an important role in tasting food, by trapping thiols produced from odorless food compounds by anaerobic bacteria living in the mouth. Saliva secretes gustin hormone which is thought to play a role in the development of taste buds.
Stimulation of saliva
•The production of saliva is stimulated both by the sympathetic and parasympathetic nervous systems.
•The saliva stimulated by sympathetic innervation is thicker, and saliva stimulated parasympathetically is more watery.
•Parasympathetic stimulation leads to acetylcholine (ACh) release onto the salivary acinar cells. ACh binds to muscarinic receptors and causes an increased intracellular calcium ion concentration (through the IP3/DAG second messenger system). Increased calcium causes vesicles within the cells to fuse with the apical cell membrane, leading to secretion formation.
•ACh also causes the salivary gland to release kallikrein, an enzyme that converts kininogen to lysyl-bradykinin. Lysyl-bradykinin acts upon blood vessels and capillaries of the salivary gland to generate vasodilation and increased capillary permeability respectively. The resulting increased blood flow to the acinar allows production of more saliva.
•Lastly, both parasympathetic and sympathetic nervous stimulations can lead to myoepithelium contraction which causes the expulsion of secretions from the secretory acinus into the ducts and eventually to the oral cavity.
Contents of saliva
Electrolytes:
•2–21 mmol/L sodium (lower than blood plasma)
•10–36 mmol/L potassium (higher than plasma)
•1.2–2.8 mmol/L calcium (similar to plasma)
•0.08–0.5 mmol/L magnesium
•5–40 mmol/L chloride (lower than plasma)
•25 mmol/L bicarbonate (higher than plasma)
•1.4–39 mmol/L phosphate
•Iodine (mmol/L usually higher than plasma, but dependent variable according to dietary iodine intake)
•Mucus in saliva mainly consists of mucopolysaccharides and glycoproteins
•Antibacterial compounds (thiocyanate, hydrogen peroxide, and secretory immunoglobulin A)
•Epidermal growth factor or EGF
•Various enzymes. There are three major enzymes found in saliva
•a-amylase (EC3.2.1.1). Amylase starts the digestion of starch and lipase fat before the food is even swallowed
•It has a pH optima of 7.4
•Antimicrobial enzymes that kill bacteria
–Lysozyme
–Salivary lactoperoxidase
–Lactoferrin
–Immunoglobulin A
–Proline-rich proteins (function in enamel formation, Ca2+-binding, microbe killing, and lubrication)
36 Therapy of Oral and Cutaneous Dryness Manifestations in Sjögren’s Syndrome |
523 |
Table 36.1 (continued)
•Minor enzymes include:
–Salivary acid phosphatases A + B, N-acetylmuramoyl-L-alanine amidase
–NAD(P)H dehydrogenase (quinone), superoxide dismutase, glutathione transferase, class 3 aldehyde dehydrogenase, glucose-6-phosphate isomerase, and tissue kallikrein (function unknown)
•Cells: Possibly as much as 8 million human and 500 million bacterial cells per mL. The presence of bacterial products (small organic acids, amines, and thiols) causes saliva to sometimes exhibit foul odor
•Opiorphin, a newly researched pain-killing substance found in human saliva
Tables 36.1 and 36.2 present a series of items that the rheumatologist may need to understand in order to communicate effectively with the dentist. These items include:
•The contents of saliva
•Biofilm
•Dental plaque and accelerated caries
•Structure of dental enamel and its dissolution based on low pH
•Role of fluoride in maintaining oral health
•Dental restorations, including veneers
•Whitening or bleaching agents for cosmetic dentistry Patients may require:
•Additional visits for their oral hygiene, ranging from every 3 to 6 months
•Topical fluoride treatment after their dental cleaning
•Use of a stronger fluoride applied by dental trays used at night
•Use of calcifying agents such as MI paste
•Topical antibiotics to retard gum recession
In individuals with SjS, there is an increase in dental caries (usually root and incisal caries), appearing as destruction around the necks of the teeth and even on the labial and incisal surfaces [32].
Dental plaque, consisting of more than 500 species of bacteria in a mature state, is a complex biofilm of microbes that adheres to the surfaces of teeth and provides a reservoir for oral microbial pathogens [33]. Streptococci account for approximately 20% of the total number of oral bacteria, and they are predominantly the first colonizers of freshly cleaned enamel surface. These bacteria are also the primary causative agents of biofilm formation and dental caries.
The bacteria normally are dislodged and expelled from the tooth surfaces and oral cavity by the mechanical forces of salivary flow and tongue movement [34]. The alteration of bacterial flora occurs with dryness due to causes other than SjS, including anxiety or medications [14].
524 |
R.I. Fox and C.M. Fox |
Table 36.2 Terminology of oral medicine
Oral biofilm
A biofilm is an aggregate of microorganisms in which cells adhere to each other and/or to oral surfaces. They play a key role in dental decay and oral candidiasis.
Biofilms have been found to be involved in a wide variety of microbial infections in the body: by one estimate, 80% of all infections including dental decay and oral candidiasis. Biofilms also are important in other mucus membranes where they influence local vaginal immunity, ocular infections, sinus and upper respiratory tract infections found more frequently in SS patients. In addition to the lubricating and antibacterial properties, these secretions may influence extracellular polymeric substance (EPS) involved in cellular recognition of specific or nonspecific attachment sites on a surface such as dental enamel, or mucosal membranes.
Dental plaque
Dental plaque is the material that adheres to the teeth and consists of bacterial cells (mainly
Streptococcus mutans and Streptococcus sanguinis), salivary polymers, and bacterial extracellular products. Plaque is a biofilm on the surfaces of the teeth. This accumulation of microorganisms subjects the teeth and gingival tissues to high concentrations of bacterial metabolites which results in dental disease.
Tooth enamel
The high mineral content of enamel, which makes this tissue the hardest in the human body, also makes it susceptible to a demineralization process which often occurs as dental caries. In SS patients, the lack of saliva leads to poor mechanical removal of bacteria, alteration of the biofilm, and a lowering of the oral pH due to the decreased volume of alkaline secretion and proteins with buffering capacity.
Sugars from candies, soft drinks, and even fruit juices play a significant role in tooth decay, and consequently in enamel destruction. The mouth contains a great number and variety of bacteria, and when sucrose, the most common of sugars, coats the surface of the mouth, some intraoral bacteria interact with it and form lactic acid, which decreases the pH in the mouth. Then, the hydroxylapatite crystals of enamel demineralize, allowing for greater bacterial invasion deeper into the tooth. The most important bacterium involved with tooth decay is Streptococcus mutans, but the number and type of bacteria varies with the progress of tooth destruction.
Oral hygiene and fluoride
Considering the vulnerability of enamel to demineralization and the daily menace of sugar ingestion, prevention of tooth decay is the best way to maintain the health of teeth in SS patients. Naturally occurring calcium fluoride is not the same as sodium fluoride, a byproduct of the fertilizer industry and the fluoride that is added to drinking water. The
recommended dosage of fluoride in drinking water depends on air temperature; in the USA, it ranges from 0.7 to 1.2 mg/L. Fluoride catalyzes the diffusion of calcium and phosphate into the tooth surface, which in turn remineralizes the crystalline structures in a dental cavity. The remineralized tooth surfaces contain fluoridated hydroxylapatite and fluorapatite, which resist acid attack much better than the original tooth did. Thus, despite fluoridation’s detractors, most dental health care professionals and organizations agree that the inclusion of fluoride in public water has been one of the most effective methods of decreasing the prevalence of tooth decay.
Dental veneer in cosmetic dentistry
Veneers were invented initially for Hollywood actors to alter the appearance of actors’ teeth. At the time, they fell off in a very short time as they were held on by denture adhesive. Today, with improved cements and bonding agents, they typically last 10–30 years.
36 Therapy of Oral and Cutaneous Dryness Manifestations in Sjögren’s Syndrome |
525 |
Table 36.2 (continued)
Veneers are an important tool for the cosmetic dentist. A dentist may use one veneer to restore a single tooth that may have been fractured or discolored, or multiple teeth to create a “Hollywood” type of makeover. Many people have small teeth resulting in spaces that may not be easily closed by orthodontics.
A problem with cosmetic dentistry in SS patients is that areas of underlying decay are no longer visible for detection or accessible to dental care and thus may progress more rapidly to tooth loss.
Tooth whitening or dental bleaching
Dental bleaching, also known as tooth whitening, is a common procedure in general dentistry but most especially in the field of cosmetic dentistry. A child’s deciduous teeth are generally whiter than the adult teeth that follow. As a person ages, the adult teeth often become darker due to changes in the mineral structure of the tooth, as the enamel becomes less porous. Teeth can also become stained by bacterial pigments, foodstuffs, and tobacco.
There are many methods to whiten teeth: bleaching strips, bleaching pen, bleaching gel, laser bleaching, and natural bleaching. Oxidizing agents such as hydrogen peroxide or carbamide peroxide are used to lighten the shade of the tooth. The oxidizing agent penetrates the porosities in the rod-like crystal structure of enamel and oxidizes interprismatic stain deposits; over a period of time, the dentin layer, lying underneath the enamel, is also bleached. Power or light-accelerated bleaching, sometimes colloquially referred to as laser bleaching, uses light energy to accelerate the process of bleaching in a dental office. Different types of energy can be used in this procedure, with the most common being halogen, LED, or plasma arc.
Although tooth bleaching may be safely done in SS patients in a dentist’s office, it should not be done by non-dental individuals who increasingly offer their services at shopping center mall kiosks, spas, salons, or other similar places. In these sites, the “amateurs” greatly accelerate the laser bleaching to save time and this may result in damage to the dental surface and gingival damage.
Even in the dentist’s office for the SS patient, it may be necessary to use lesser quantities of lightening agents or to perform on alternate days (rather than on a single day). Even when these precautions are taken, side effects of dental bleaching may include chemical burns from gel bleaching (if a high-concentration oxidizing agent contacts unprotected tissues, which may bleach or discolor mucous membranes) and sensitive teeth. It is worth advising patients who ask that nearly half the initial change in color provided by an intensive in-office treatment (i.e., 1-h treatment in a dentist’s chair) may be lost in 7 days. Rebound tooth sensitivity is experienced due to a dehydration of the tooth.
Certain tooth whitening “tooth pastes” have an overall low pH, which can put enamel at risk for decay or destruction by demineralization. Consequently, care should be taken and risk evaluated when choosing a product which is very acidic. Also, tooth whiteners in toothpastes work through a mechanical action. They have mild abrasives which aid in the removal of stain but also may weaken dental enamel.
SjS, as well as other conditions including xerostomia associated with aging, also increases a person’s likelihood of contracting opportunistic infections such as oral candidiasis and the proliferation of cariogenic microorganisms [35].
A study demonstrated that persons with primary SjS were reported to have higher numbers of cariogenic and acidophilic microorganisms in comparison with those found in control individuals [36].
526 |
R.I. Fox and C.M. Fox |
Another comprehensive study, carried out with interviews and clinical oral examinations of 53 persons with primary SjS and 53 age-matched control individuals, found that those with primary SjS had more teeth extracted, more problems with their teeth in their lifetime, and higher dental expenses, compared with the control group.
In a separate study [37], the number of decayed, missing, or filled teeth was higher in both the younger and older groups of persons with primary SjS, compared with the normal control individuals. The young persons had, on average, seven teeth missing, compared with two missing in the control individuals. Those with primary SjS had more frequent dental visits compared with control individuals.
Even with excellent oral hygiene, individuals with SjS have elevated levels of dental caries, along with the loss of many teeth early in the disease. Pedersen et al. [36] reported that persons, who brushed their teeth with toothpaste containing fluoride and visited their dentist more frequently, still had higher numbers of missing, filled, and decayed teeth, along with a higher gingival index.
Fluoride is an extremely important element in the prevention of dental caries [32, 38–42]. However, certain regions do not maintain fluoridation in the water supply; patients living in these areas are at particular risk. In addition, the increasing use of non-fluoridated bottled water in place of fluoridated tap water is having a profound effect in decreasing fluoride exposure for many patients.
Topical fluoride promotes remineralization of teeth by the development of a crystalline protective veneer at the site of demineralization and inhibition of bacterial metabolism and acid production. Fluoride may be applied in various forms, depending on the severity of disease, including mouth rinses, fluoride gels applied at home in custom-fitted trays, and by dental office-based application of fluoride varnish [32, 38–42].
Chemoprophylaxis – Several approaches may be taken in an effort to reduce oral bacterial flora, including the use of chlorhexidine (CHX), a topical antimicrobial agent, and products containing baking soda, bicarbonate, or xylitol (see below) [32, 43–45]. In addition, CHX has an antifungal affect that may also benefit patients with SjS. CHX may also be used to soak dentures overnight. Dentures may be a source of bacterial infection as well as recurrent candida infection, and patients should not wear dentures overnight.
Polyol sweeteners, such as xylitol and sorbitol that are not fermentable by acidproducing bacteria, are of low cariogenic or noncariogenic potential; they may prevent or limit demineralization and promote the remineralization process. Xylitol may be a useful adjunct to other anti-caries treatments, but should not be considered in patients with SjS as a substitute for fluoride or other well-established interventions [46, 47].
Patients with SjS may have more difficulty wearing dentures because of the decreased moisture in the mouth. No adequately controlled clinical trials have addressed this question. In general, dentures cannot replicate the efficiency and comfort of natural teeth.
There are scattered case reports regarding the ability of patients with SjS to handle dental implants, although the often-poor status of oral tissues and bone loss in SjS patients may cause difficulty. The majority of reports for SjS patients appear favorable, but do not provide long-term follow-up [48, 49]. Decisions regarding use of
